Tyme Technologies Inc (TYME) Stock
TYME is no longer traded. Tyme Technologies was delisted from the Nasdaq in September 2022.
Prices on this page are historical; the last trade was September 16, 2022 at $0.31.
Tyme Technologies stock price history
TYME final trading statistics
- Final close
- $0.31
- Final trading day
- Sep 16, 2022
- Market cap at delisting
- $53.50M
- Shares outstanding
- 172.21M
- Final 52-week range
- $0.22 – $1.14
- Avg. volume (final 3 mo.)
- 1,407,817
- All-time high (split-adj.)
- $11.25 · Dec 2015
- All-time low (split-adj.)
- $0.01 · Mar 2013
- Return since IPO
- +3277.2%
- Beta
- 0.92
- Book value / share
- $0.43
- Price / book
- 0.72
Tyme Technologies annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$23.6M | -$0.19 |
| FY2021 | $0.00 | -$29.0M | -$0.21 |
| FY2020 | $0.00 | -$22.0M | -$0.18 |
| FY2019 | $0.00 | -$33.0M | -$0.32 |
| FY2018 | $0.00 | -$19.0M | -$0.21 |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Tyme Technologies Inc
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
Tyme Technologies stock FAQ
What happened to Tyme Technologies stock?
Tyme Technologies stock was delisted from the Nasdaq. Its final close was $0.31 on September 16, 2022.
Is TYME stock still trading?
No. TYME was delisted from the Nasdaq in September 2022 and no longer trades on a U.S. exchange.
What was the last price of TYME stock?
TYME closed at $0.31 on its final trading day, September 16, 2022, for a market value of about $53.50M.
What were Tyme Technologies's revenue and earnings in its last full fiscal year?
Tyme Technologies reported revenue of $0.00 and net income of -$23.6M in fiscal 2022, its last full year as a public company.
When did Tyme Technologies go public?
Tyme Technologies Inc stock began trading on March 12, 2015.